Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone ...

An international trial found combining a chemotherapy drug with an immunotherapy bladder cancer treatment is simple, safe and ...

ASCO annual meeting featured a urothelial carcinoma oral abstract session and a discussant presentation by Dr. John Sfakianos ...

A decades-old TB vaccine turned cancer therapy may unlock new immunotherapies by reprogramming immune cell development in the ...

Anorexia: a loss of appetite caused by illness or treatment, not the eating disorder. Hematuria: blood in the urine. “[Aidixi] plus BCG may potentially provide ... department of Urology, Fudan ...

Cretostimogene monotherapy achieves a 75.5% complete response rate in high-risk, BCG-unresponsive non-muscle invasive ... at the 40th Annual European Association of Urology Congress in Madrid, Spain, ...

7 Current treatment options for BCG-unresponsive patients are very limited ... medicine with a strong heritage in gastroenterology and urology, and are at the forefront of innovation in uro ...

U.S. Urology Partners is one of ... Supply shortages of TICE BCG in the U.S. have become a significant impediment to the treatment of bladder cancer patients. In a recent Sermo survey of 100 ...

a Phase 3 clinical trial for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) therapy. Cretostimogene is ...

“I’m pleased U.S. Urology is at the forefront of offering ... receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non ...